Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.83 |
| ▸ | MAT2A | P31153 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197375 | 0.91 | TSPO (1.00) | TSPOMAT2AMAPT | |
| SCHEMBL14300517 | 0.88 | TSPO (0.80) | TSPOMAT2AMAPT | |
| SCHEMBL7496839 | 0.87 | TSPO (0.82) | TSPOMAT2AMAPT | |
| SCHEMBL5702540 | 0.86 | TSPO (0.81) | TSPOMAT2AMAPT | |
| SCHEMBL8959267 | 0.86 | TSPO (0.75) | TSPOMAT2AMAPT | |
| SCHEMBL7721134 | 0.83 | TSPO (0.76) | TSPOMAPT | |
| SCHEMBL5702522 | 0.82 | TSPO (0.74) | TSPOMAT2AMAPT | |
| SCHEMBL10042107 | 0.82 | TSPO (0.84) | TSPOMAPT | |
| SCHEMBL5745978 | 0.82 | TSPO (0.84) | TSPOMAT2AMAPT | |
| SCHEMBL17959423 | 0.82 | TSPO (0.83) | TSPOMAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841320-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY | 2014-09-23 | — | — | US | disclosed |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | VANDERBILT UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| US-8372868-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2013-02-12 | — | — | US | disclosed |
| US-8188116-B2 | Ligand/drug conjugates; near infrared radiation imaging; peripheral benzodiazepine receptor imaging; drug delivery; drug targets; cancer, metastasis | VANDERBILT UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | VANDERBILT UNIVERSITY | 2010-11-04 | — | — | US | disclosed |
| US-7754884-B2 | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | VANDERBILT UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | US GOVERNMENT - SECRETARY FOR THE ARMY | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031823-A1 | AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING | TSPO, MKI67, CNR1 | TSPO 1/4885MAT2A 4737/4885MAPT 2490/4885 |
| US-20100278739-A1 | TARGETED, NIR IMAGING AGENTS FOR THERAPY EFFICACY MONITORING, DEEP TISSUE DISEASE DEMARCATION AND DEEP TISSUE IMAGING | TSPO, MKI67, GABRA4 | TSPO 1/4885MAT2A 4526/4885MAPT 1399/4885 |
| US-20130177502-A1 | Targeted, NIR Imaging Agents for Therapy Efficacy Monitoring, Deep Tissue Disease Demarcation and Deep Tissue Imaging | TSPO, MKI67, GABRA4 | TSPO 1/4885MAT2A 4526/4885MAPT 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.